MAOB and Parkinson disease: To counter the effect of dopaminergic neural deaths, pharmacological agents such as levodopa, dopamine agonists, and monoamine oxidase type B inhibitors (MAO-B inhibitors) have been used to increase the intracerebral dopamine level or to stimulate the dopamine receptors in PD patients.